PTGX - Protagonist Therapeutics, Inc

105.47
-0.510   -0.484%

Share volume: 536,526
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$105.98
-0.51
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 9%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.68%
1 Month
7.03%
3 Months
25.72%
6 Months
40.63%
1 Year
130.28%
2 Year
296.35%
Key data
Stock price
$105.47
P/E Ratio 
0.00
DAY RANGE
$104.00 - $106.46
EPS 
-$2.05
52 WEEK RANGE
$41.28 - $107.84
52 WEEK CHANGE
$130.03
MARKET CAP 
5.460 B
YIELD 
N/A
SHARES OUTSTANDING 
63.809 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
0.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$778,142
AVERAGE 30 VOLUME 
$780,117
Company detail
CEO: Dinesh V. Patel
Region: US
Website: protagonist-inc.com
Employees: 120
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.

Recent news